企業プロフィール
Sarepta Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- SRPT
- 取引所:
- NASDAQ
- セクター:
- Gene Therapy
- 所在地:
- United States
株価パフォーマンス
18.18 USD (+0.44%)
終値
最終更新: 2026年8月17日
1.72B USD
時価総額
株価変動の要因
As of Aug 17, 2026, SRPT closed up 0.44% at $18.18. No new same-company headline was identified in the current news window.
企業概要
Precision Genetic Medicine
Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.
ELEVIDYS
ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and older with confirmed Duchenne mutations.
Exon-Skipping Franchise
EXONDYS 51, VYONDYS 53 and AMONDYS 45 use phosphorodiamidate morpholino oligomers to skip specific dystrophin exons in genetically eligible Duchenne patients.
siRNA Platform
SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Global Commercial Partnerships
Sarepta commercializes directly in the United States and works with Roche and Chugai on ELEVIDYS outside the U.S., combining internal development with regional partnerships.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。